Amlodipine/rosuvastatin/valsartan - CJ Healthcare

Drug Profile

Amlodipine/rosuvastatin/valsartan - CJ Healthcare

Alternative Names: CJ-30060

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator CJ HealthCare
  • Class
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hyperlipidaemia; Hypertension

Highest Development Phases

  • Phase III Hyperlipidaemia; Hypertension

Most Recent Events

  • 11 Jul 2016 Chemical information added
  • 01 Jan 2016 Amlodipine/rosuvastatin/valsartan - CJ Healthcare is available for worldwide licensing as of 01 Jan 2016. www.cjp.co.kr
  • 24 Dec 2015 Phase-III clinical trials in Hyperlipidaemia in South Korea (PO) prior to December 2015 (CJ Healthcare pipeline, December 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top